ReviewInternational journal of molecular sciences2023
Cholesterol Remnants, Triglyceride-Rich Lipoproteins and Cardiovascular Risk.
Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Artificial intelligence in computational modeling of thrombosis: Bridging mechanistic insights and clinical translation.Journal of thrombosis and thrombolysis · 2026Pooled it
- Circulating Levels of Remnant Cholesterol as Potential Biomarkers for Predicting Gestational Diabetes: A Systematic Review.Journal of diabetes research · 2026Pooled it
- Trial
- Atherogenic Burden and Remnant Cholesterol Associate With Electrophysiological Severity in Carpal Tunnel Syndrome.Brain and behavior · 2026Article
- Metabolomic signature reveals dysregulated lipoprotein profile in m.3243A>G carriers: a case-control study.Metabolomics : Official journal of the Metabolomic Society · 2026Article
- Correlation Between the Atherogenic Index of Plasma and Major Adverse Long-Term Prognosis in Patients With Coronary Artery Disease and Stage 2-5 Chronic Kidney Disease.Reviews in cardiovascular medicine · 2026Article
- Beyond traditional risk factors: the impact of cumulative inflammation and remnant cholesterol on myocardial infarction in a prospective cohort study.Lipids in health and disease · 2026Article
- Association of mid-pregnancy remnant cholesterol levels with adverse pregnancy outcomes in women with gestational diabetes mellitus.BMC pregnancy and childbirth · 2026Article
- Remnant Cholesterol Inflammatory Index and Its Association With All-Cause Mortality Among General Population and Individuals With Cardiovascular-Kidney-Metabolic Syndrome Stages 0-3: Evidence From Two Nationwide Studies.Clinical cardiology · 2026Article
- Drug-associated deep vein thrombosis: a disproportionality analysis of the FDA adverse event reporting system (FAERS) database.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- The remnant cholesterol inflammatory index and risk of future cardiovascular disease in early CKM syndrome: findings from CHARLS.Journal of health, population, and nutrition · 2026Article
- Residual risk in atherosclerotic cardiovascular disease after statin therapy: Clinical mechanisms and management strategies.World journal of cardiology · 2026Review
- Remnant cholesterol inflammatory index and its association with new-onset chronic diseases: evidence from two nationwide studies.Journal of health, population, and nutrition · 2026Article
- Reduced activity of two LPL C-terminal variants, p.Glu396Val and novel p.Trp417Cys: a clinical, biochemical and structural study.Frontiers in physiology · 2026Article
- The association of remnant cholesterol inflammatory index with the risk of major adverse cardiovascular events in patients with angina undergoing percutaneous coronary intervention: a retrospective study.Frontiers in cardiovascular medicine · 2026Article
- Association of lipoprotein indices with 3-month functional outcome after ischemic stroke: a retrospective cohort study.Frontiers in nutrition · 2026Article
- The Role of Triglycerides in the Development of Atherosclerosis.Acta medica Lituanica · 2026Review
- Association of cumulative remnant cholesterol exposure with adverse outcomes after PCI in acute ST-segment elevation myocardial infarction.Frontiers in cardiovascular medicine · 2026Article
- A Narrative Review of Remnant Cholesterol as an Independent Atherogenic Lipoprotein in Type 2 Diabetes: Pathophysiology and Clinical Implications.Therapeutics and clinical risk management · 2026Review
- Novel lipid parameters for predicting and interpreting the severity of coronary artery lesions in premature coronary artery disease.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Randomized clinical trials with statins and other lipid-lowering drugs have shown the presence of a "residual cardiovascular risk" in those treated to "target" for LDL-cholesterol. This risk is mainly associated to lipid components other than LDL and in particular to remnant cholesterol (RC) and to lipoproteins rich in triglycerides in fasting and non-fasting conditions. During fasting, RCs correspond to the cholesterol content of the VLDL and their partially depleted triglyceride remnant containing apoB-100. Conversely, in non-fasting conditions, RCs include also cholesterol present in chylomicrons containing apoB-48. Therefore, RCs refer to total plasma cholesterol minus HDL-cholesterol and LDL-cholesterol, that is, all the cholesterol present in the VLDL, chylomicrons and in their remnants. A large body of experimental and clinical data suggests a major role of RCs in the development of atherosclerosis. In fact, RCs easily pass the arterial wall and bind to the connective matrix stimulating the progression of smooth muscle cells and the proliferation of resident macrophages. RCs are a causal risk factor for cardiovascular events. Fasting and non-fasting RCs are equivalent for predicting vascular events. Further studies on drugs effect on RC levels and clinical trials to evaluate the efficacy of RC reduction on cardiovascular events are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.